Lexaria Bioscience Corp.: Lexaria Announces Positive Feedback from Pre-IND Meeting with FDA on DehydraTECH-CBD for Hypertension
Significant Milestone Achieved in Commercial Product Development ProgramAbbreviated 505(b)(2) Strategy Confirmed as an Appropriate NDA PathwayKELOWNA, BC / ACCESSWIRE / August 10, 2022 / Lexaria Bioscience
Source: finanznachrichten.de